Defence Therapeutics Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DTCFF research report →
About the company
Defence Therapeutics Inc. develops a biological drug enhancer platform that improves the efficacy and safety of a multitude of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on the research, development, and advancement of products using its Accum technology, including antibody drug conjugates targeting various cancers; the anti-cancer AccuTOX program, which has completed preclinical studies for solid T-cell lymphoma, breast cancer, and melanoma; the ARM-X vaccine program, a mesenchymal stem cell-based vaccine targeting cancer; and mRNA vaccination program.
- CEO
- Sébastien Plouffe
- IPO
- 2021
- Employees
- 1,300
- HQ
- Vancouver, QC, CA
Price Chart
- Market Cap
- $17.82M
- P/E
- -3.89
- P/S
- 0.00
- P/B
- 4.74
- EV/EBITDA
- -5.20
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -1661.38%
- ROIC
- -53.54%
- Revenue
- $0 · 0.00%
- Net Income
- $-4,000,000 · 69.68%
- EPS
- $-0.05 · 82.70%
- Op Income
- $-3,000,000
- FCF YoY
- 33.21%
- 52W High
- $0.78
- 52W Low
- $0.29
- 50D MA
- $0.37
- 200D MA
- $0.46
- Beta
- 1.35
- Avg Volume
- 7.69K
Get TickerSpark's AI analysis on DTCFF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our DTCFF coverage
Recent articles, reports, and earnings notes.
No research on DTCFF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate DTCFF report →Similar companies
Peers in the same neighborhood.